COURSE - BRAZILIAN SCHOOL OF MASTOLOGY
FACE-TO-FACE

Coordinators:
ALEXANDRE MARCHIORI XAVIER DE JESUS (BRA)
CAROLINA FUSCHINO (BRA)
GUILHERME NOVITA GARCIA (BRA)

EDUARDO CARVALHO PESSOA (BRA)

PART 1 - SURGERY AGENDA

Speaker:
EDUARDO CARVALHO PESSOA (GO)

Multifocal Breast Cancer and conserving surgery

1)  Are we authorized?
2) What are the criteria? For both multifocality and multicentricity? Haw many tumors?
3) What is the best surgical approach?
4) What about radiation therapy? More than a boost? Should we clip all tumor beds?
5) Do we have enough time in terms of studies? Luminal diseases relapse more in the long run.

Surgery planning in the conserving surgery

1)  What are the key axams to request in order to schedule a conserving surgery in dense breasts?
2) Is mamography enough for liposubstituted breast?
3) Does the Brazilian randomized study - breast MRI triel - MRI impact in surgery planning rule out MRI of our routine?
4) Can we evaluate surgical margins with intraop ultrasound of the specimen?

Discussion

ROBERTO KEPLER DA CUNHA AMARAL (BRA)
ROGÉRIO BIZINOTO FERREIRA (BRA)

JOÃO BOSCO RAMOS BORGE (BRA)

PART 2 - TREATMENT AND CHEMOPROPHYLAXIS

Speaker:
JOÃO BOSCO RAMOS BORGES (BRA)

Pregnancy after breast cancer

1) With positive trial - pregnancy after breast cancer - can we ensure that getting pregnant is safe for breast-cancer survivors?
2) Is there robust data?
3) Would all molecular types be covered? For luminal diseases, what is the appropriate time?

Chemoprophylaxis

1)  What is best strategy?
2) SERMs, SERDs, IAs?
3) Which dose? For how long? Do we have an algorithm?
4) In risk-posing lesions, prescription is made without hormonal recptors assessment.
What happens when it comes to invasive Ductal Carcinoma(IDCs)?

Discussion

DANILO ARAUJO DE GUSMÃO (BRA)
DÉBORA SARA DE ALMEIDA CARDOSO PEIRÓ (BRA)

Coffee Break

FRANKLIN FERNANDES PIMENTEL (BRA)

PART 3 - SYSTEMIC TREATMENT FOR THE SURGEON

Speaker:
FRANKLIN FERNANDES PIMENTEL (BRA)

Treatment sequence

1) Considering no iatrogenesis, which patients must necessarily be referred to neoadjuvant chemotherapy?
2) Should we avoid performing surgery in elderly patients? Which cases?
3) When can/can't we approach the axilla?
4) Is there still room for locoregional treatment in the metastatic disease setting?

Discussion

MARCELO ANTONINI (BRA)
MONICA TRAVASSOS JOURDAN DE ARAÚJO-JORGE (BRA)

Genomic platforms

1)  Oncotype, Mammaprint, BCI and what else? For whom, why and when?

Discussion

FABIO POSTIGLIONE MANSANI (BRA)
PATRÍCIA WERLANG SCHORN (BRA)

BREAST IMAGING WORKSHOP
HYBRID + WITH TRANSLATION

Coordinators:
HENRIQUE LIMA COUTO (BRA)
JOSÉ LUIS ESTEVES FRANCISCO (BRA)

Maria Júlia Gregório Calas (BRA)

MODULE 1 - CONFERENCE

Coordinator:
MARIA JÚLIA GREGÓRIO CALAS (BRA)

RITSE MANN (NLD)

Screening breast cancer in dense breast: the dense trial initiative

RITSEN MANN (NLD)

Discussion

JULIANA NORMANHA (BRA)

MODULE 2 - IGR SYMPOSIUM – THE ROLE OF NEW TECHNOLOGIES IN THE EARLY DIAGNOSIS AND STAGING OF BREAST CANCER

Coordinator:
JULIANA NORMANHA RESENDE (BRA)

MARCIO MITSUGUI SAITO (BRA)

Contrast enhanced mammography

MARCIO MITSUGUI SAITO (BRA)

JULIANA NORMANHA (BRA)

Breast tomosynthesis in breast cancer screening and diagnosis

JULIANA NORMANHA RESENDE (BRA)

DANIELE MENDONÇA

Patient with recent diagnosis of breast cancer: what is the role of MRI?

DANIELE MACHADO MENDONÇA (BRA)

Discussion

Coffee Break

Maria Júlia Gregório Calas (BRA)

MODULE 3 - ADVANCED BREAST CANCER IMAGING MODALITIES

Coordinator:
MARIA JÚLIA GREGÓRIO CALAS (BRA)

POOJA JAGMOHAN (SGP)

Implementing CESM in practice: the Singapore experience

POOJA JAGMOHAN (SGP)

LINEI AUGUSTA BROLINI DELLÊ URBAN

Breast cancer screening in high risk women

LINEI AUGUSTA BROLINI DELLÊ URBAN (BRA)

PALAK BHAVESH POPAT (IND)

Stepping beyond core biopsies-spectrum of vacuum assisted breast biopsies

PALAK BHAVESH POPAT (IND)

Discussion

RACHEL MACHADO DE OLIVEIRA PORTELA (BRA)

MODULE 4 - ELA DIAGNOSIS SYMPOSIUM - UPDATING THE DIAGNOSTIC APPROACH OF NON-PALPABLE BREAST LESIONS

Table coordinator:
RACHEL MACHADO DE OLIVEIRA PORTELA (BRA)

SIMONE ELIAS (BRA)

Non-palpable breast Lesions: what type of biopsy is most suitable for each case?

SIMONE ELIAS (BRA)

MARIANA MESQUITA GOMES CAITANO (BRA)

Vacuum Assisted Biopsy (VAB): practical considerations and management of challenging cases

MARIANA MESQUITA GOMES CAITANO (BRA)

HENRIQUE LIMA COUTO (BRA)

Facing the Lamb x Wolf Dilemma: A New Guideline Incorporating Vacuum Assisted Excision in Routine Practice

HENRIQUE LIMA COUTO (BRA)

MÔNICA ALVARES LEÃO (BRA)

Discussion

MÔNICA ALVARES LEÃO (BRA)

Pollyanna Dornelas Pereira (BRA)

MODULE 5 - CONFERENCE

Coordinator:
POLLYANNA DORNELAS PEREIRA (BRA)

JULIA CAMPS HERRERO (ESP)

Innovative use of VAB in order to avoid MR-guided biopsies of additional lesions seen in BC staging

JULIA CAMPS HERRERO (ESP)

Discussion

Coffee Break

Barbara Pace Silva de Assis Carvalho

MODULE 6

Coordinator:
BARBARA PACE SILVA DA ASSIS CARVALHO (BRA)

EDUARDO CARVALHO PESSOA (BRA)

Important aspects of breast anatomy in imaging exams for the surgeon

EDUARDO CARVALHO PESSOA (BRA)

SARA E VÁZQUEZ MANJARREZ (MEX)

Breast imaging challenging cases: CESM to the rescue

SARA E VÁZQUEZ MANJARREZ (MEX)

HENRIQUE LIMA COUTO (BRA)

Digital breast tomosynthesis added to synthetic mammography (DBT + 2Ds) in Brazilian screening program (BCS): clinical and economic impact

HENRIQUE LIMA COUTO (BRA)

Discussion

ONCOPLASTY WORKSHOP

8^th STUDENTS AND ALUMNI MEETING OF THE CONTINUED EDUCATION PROGRAM ON ONCOPLASTY AND BREAST RECONSTRUCTION HOSTED BY HOSPITAL ARAÚJO JORGE AND AMARAL CARVALHO HOSPITAL

HYBRID + WITH TRANSLATION

Coordinators:
CICERO DE ANDRADE URBAN (BRA)
MAURÍCIO DE AQUINO RESENDE (BRA)
REGIS RESENDE PAULINELLI (BRA)

Opening:
REGIS RESENDE PAULINELLI (BRA)

MAURÍCIO DE AQUINO RESENDE (BRA)

SESSION 1 - NEW PERSPECTIVES WITHIN BREAST RECONSTRUCTION

Coordinator
MAURÍCIO DE AQUINO RESENDE (BRA)

RAGHAVAN VIDYA (UK)

Anatomical or round implants in breast reconstruction? New trends

RAGHAVAN VIDYA (UK)

BENIGNO ACEA (ESP)

Polyurethane-coated, smooth or textured implants. What is the future of reconstruction with implants?

BENIGNO ACEA NEBRIL (ESP)

YAZAN MASSANAT (UK)

The future of ADM in breast reconstruction

YAZAN MASSANAT (UK)

ABHISHEK CHATTERJEE (USA)

Autologous or heterologous breast reconstruction? Cost-effectiveness

ABHISHEK CHATTERJEE (USA)

Discussion

Coordinator
AUGUSTO TUFI HASSAN (BRA)
FRANCISCO ABED (PAR)
MARCO AURÉLIO TROVÓ (BRA)

CÍCERO DE ANDRADE URBAN (BRA)

SESSION 2- HOT TOPICS

Coordinator:
CÍCERO DE ANDRADE URBAN (BRA)

What is the best plan for reconstruction with implants?

10’ Prepectoral EDUARDO GONZALES (ARG)
10’ Retropectoral FABRICIO PALERMO BRENELLI (BRA)

Contralateral mastectomy?

10’ Yes JILL DIETZ (USA)
10’ No ASHUTOSH KOTHARI (UK)

Discussion

AGUIAR FARINA (BRA)
DANIEL MEIRELLES BARBALHO (BRA)
FÁBIO BAGNOLI (BRA)
HASAN KARANLIK (TUR)

Coffee Break

JOÃO RICARDO EULER PALOSHI (BRA)

SESSION 3 - INNOVATIVE TECHNIQUES - VIDEOS

Coordinator
JOÃO RICARDO AULER PALOSHI (BRA)

RICARDO PARDO (ENG)

Lateral Thoracic Artery Perforator (LTAP)

RICARDO PARDO (ENG)

RÉGIS RESENDE PAULINELLI (BRA)

Thoracolateral type VY advancement flap

RÉGIS RESENDE PAULINELLI (BRA)

VILMAR MARQUES DE OLIVEIRA (BRA)

Autologous reconstruction with the latissimus dorsi – personal preference

VILMAR MARQUES DE OLIVEIRA (BRA)

JORGE VILLANOVA BIAZUS (BRA)

Nano-fat grafting in breast reconstruction

JORGE VILLANOVA BIAZUS (BRA)

Chaitanyanand Koppiker (IND)

Autologous lower dermal sling in breast reconstruction

CHAITANYANAND BALKRISHNA KOPPOKER (IND)

Discussion

ANTONIO TEJERINA (ESP)
GASTÓN BERMAN (ARG)
NICOLA ROCCO (ITA)

LUIZ FERNANDO JUBÉ RIBEIRA (BRA)

SESSION 4 - BEST ONCOPLASTY VIDEO - CONTEST

Coordinator
LUIZ FERNANDO JUBÉ RIBEIRO (BRA)

Lígia Maria Teixeira Pereira Porciuncula (BRA)

Eliminating the classic scar of the lipofilled dorsal mini flap in post-nipple sparing mastectomy reconstruction

LÍGIA MARIA TEIXEIRA PEREIRA PORCIUNCULA (BRA)

Ana Filipa Ferreira Goulart (BRA)

Multiple myocutaneous flaps for closing a large thoracic defect

ANA FILIPA FERREIRA GOULART (BRA)

Discussion

JAIME LETZKUS (CHI)
RODRIGO CERICATTO (BRA)

Ailton Joioso (BRA)

SESSION 5 - CONFERENCE

Coordinator:
AILTON JOIOSO (BRA)

GIUSEPPE CATANUTTO (ITA)

The oncoplastic surgery of the future

GIUSEPPE CATANUTTO (ITA)

Closing

CÍCERO DE ANDRADE URBAN (BRA)
MAURÍCIO DE AQUINO RESENDE (BRA)
REGÍS RESENDE PAULINELLI (BRA)

Confraternization dinner

(Pre-registration)

NANOMEDICINE WORKSHOP
ON-LINE + NO TRANSLATION

Coordinator:
ANDRIS FIGUEIROA BAKUZIS (BRA)
ROBERT IVKOV (USA)

ONDREJ HOVORKA (UK)

Basic physical principles of magnetic particle imaging

ONDREJ HOVORKA (UK)

Costa G Hadjipanayis (USA)

Magnetic hyperthermia and brain cancer: a nanomedicine solution

COSTA G HADJIPANAYIS (USA)

ERVING CLAYTON XIMENDES (SPA)

Unveiling the near-infrared autofluorescence of glioblastoma through hyperspectral imaging: a murine study

ERVING CLAYTON XIMENDES (SPA)

Carla Martí Castello (SPA)

Immunomodulatory effect of photothermal therapy for canine breast Cancer

CARLA MARTÍ CASTELLÓ (SPA)

LÍVIA PALMERSTON MENDES (GER)

The potential of lipid nanoparticles as a delivery platform for mRNA vaccines in cancer immunotherapy

LIVIA PALMERSTON MENDES (GER)

Discussion

ELIANA MARTINS LIMA (BRA)

Nose to brain nanotechnology for cancer therapy

ELIANA MARTINS LIMA (BRA)

Eder José Guidelli (BRA)

Four generations of nanoparticles to boost radiotherapy efficacy

EDER JOSÉ GUIDELLI (BRA)

Severino Alves Jr (BRA)

Metal organic frameworks: from luminescent marker for gunshot residues to theranostic therapy

SEVERINO ALVES JR (BRA)

MARCUS VINICIUS ARAÚJO (BRA)

Core-shell structured NaYF4:Nd3+/Yb3+/Ho3+ nanoparticles as a promising probe for real-time temperature sensing and 3D fluorescence imaging

MARCUS VINÍCIUS DE ARAÚJO (BRA)

Carlos Jacinto da Silva (BRA)

Artificial intelligence-assisted optical nanothermometry for more accurate temperature detection

CARLOS JACINTO DA SILVA (BRA)

JASON STAFFORD (USA)

MRI-guided thermal therapy: from bench to bedside

JASON STAFFORD (USA)

Discussion

Lunch

PATRICK GOODWILL (USA)

Magnetic particle imaging: are we close to the clinic?

PATRICK GOODWILL (USA)

HAYDEN CARLTON (USA)

Method to evaluate merit of magnetic nanoparticles for applications with magnetic particle imaging and magnetic nanoparticle hyperthermia

HAYDEN CARLTON (USA)

Antônio Adilton Oliveira Carneiro (BRA)

Improvement of ultrasound-guided theranostic applications using hybrid nanoparticles

ANTÔNIO ADILTON OLIVEIRA CARNOIRO (BRA)

Guilherme Soares (BRA)

Instrumentation and applications of alternating current biosusceptometry: imaging and biodistribution of magnetic nanoparticles

GUILHERME SOARES (BRA)

JULIANA CANCINO-BERNARDI (BRA)

Recent progress in nanomedicine: from diagnosis to therapy

JULIANA CANCINO-BERNARDI (BRA)

Discussion

PREETHI KORANGATH (USA)

Nanoparticle - immune cell interactions in the context of cancer

PREETHI KORANGATH (USA)

JOÃO PAULO FIGUEIRÓ LONGO (BRA)

Preventive and therapeutic vaccine for an aggressive metastatic murine breast tumor model produced with cells under immunogenic cell death

JOÃO PAULO FIGUEIRÓ LONGO (BRA)

AILTON ANTONIO SOUSA JUNIOR (BRA)

Enhancing survival in sarcoma model via photothermal therapy mediated by erythrocyte-membrane camouflaged manganese-ferrite nanoparticles

AILTON ANTÔNIO DE SOUSA JR (BRA)

Willie Oliveira Pinheiro (BRA)

The influence of pequi oil combined with magnetic hyperthermia and selol in the mice breast cancer treatment

WILLIE OLIVEIRA PINHEIRO (BRA)

Nicole Levi (USA)

Photothermal nanoparticles for treating breast cancer

NICOLE LEVI (USA)

Discussion

CLINICAL RESEARCH WORKSHOP
ONLINE + NO TRANSLATION

Coordinators
ANDRÉ MATTAR (BRA)
JOSÉ LUIZ PEDRINI (BRA)
ROBERTO HEGG (BRA)

MODULE 1 - HOMOWORK FOR CLINICAL RESEARCH

Coordinators:
ANDRÉ MATTAR (BRA)
LARISSA ANDRESSA ORSOLINI (BRA)

RUFFO DE FREITAS JUNIOR (BRA)

Opening

RUFFO DE FREITAS JUNIOR (BRA)

SUSANNE CROCAMO (BRA)

Current clinical research setting in the word and in Brazil, where are we now?

SUSANNE CROCAMO (BRA)

1) Research data wordwide
2) Research data in Brazil
3) What do we need to do to be better?

VIVIENNE CASTILHO (BRA)

What does the industry seek in a research center?

VIVIENNE CARDUZ CASTILHO (BRA)

1) What is the benchmark for clinical research center in Brazil?
2) The difference between practice in clinical oncology and research in clinical oncology
3) Minimum infrastructure

DIOCÉSIO ALVES PINTO DE ANDRADE (BRA)

What do centers expect from a clinical trial sponsor?

DIOCÉSIO ALVES PINTO DE ANDRADE (BRA)

1) The best sponsor´s practice
2) How important is budget?
3) What are the biggest difficulties with the sponsor?

Q & A

Coffee Break

MODULE 2 - RESEARCH CENTER MANAGEMENT SESSION

Table coordinator:
FRANKLIN FERNANDES PIMENTEL (BRA)
JOSE LUIZ PEDRINI (BRA)

ROBERTO HEGG (BRA)

How to start an oncology research center?

ROBERTO HEGG (BRA)

1) Minimal infrastructure needed
2) Regulatory process
3) Tips: what is essential?

ISABELA BASSO DOS SANTOS TRINDADE (BRA)

Is there a way to speed up the regulatory process?

ISABELA BASSO DOS SANTOS TRINDADE (BRA)

1) Is there a quicker way to evaluate the contract?
2) Is there a way to predict IRB Pendency?
3) Tips: what is the best way to start a trial?

KAMYLLA DA SILVA CALDEIRA (BRA)

Clinical research budget and agreement analysis: How to turn it indo a sustainable Center?

KAMYLLA DA SILVA CALDEIRA (BRA)

1) Are the contracts the same?
2) Is there a better way to analyze the contract?
3) Tips: is there any way to get more from a sponsor?

KATSUKI ARIMA TISCOSKI (BRA)

How to increase the number of trials without underminig data quality?

KATSUKI ARIMA TISCOSKI (BRA)

1) In a starting center: is there better way to increase the numbers os trials?
2) In a well stablished center: anything to add?
3) Tips: what is possible to be done to obtain good quality of data without much more work?

Q & A

MODULE 3 - FEASIBILITY, RECRUTING, CONDUCTING AND RETENTION

Coodinators:
MAGDA CONCEIÇÃO BARBOSA GOMES (BRA)
ROBERTO HEGG (BRA)

JOSÉ LUIZ PEDRINI (BRA)

The feasibility process: is there a best way to do it?

JOSE LUIZ PEDRINI (BRA)

1) Is it adequate to always accept the trial?
2) Are there any ways to better estimate commitment?
3) Tips: how to make sure that the center has the structure and the right patients?

CRISTIANO DE PÁDUA SOUSA (BRA)

Recruitment strategy for breast cancer trials.

CRISTIANO DE PÁDUA SOUZA (BRA)

1) Whats options are available to recruit the right patients?
2) Is social media are effective?
3) Tips: is there any help from the sponsor than can be used?

ROMUALDO BARROSO DE SOUSA (BRA)

Is there any difference in conducting a phase 1 trial?

ROMUALDO BARROSO DE SOUSO (BRA)

1) Which barriers must be broken?
2) What are the greatest concerns in phase 1 trials?
3) Tips: how to persuade the sponsor that your center is ready for a phase 1 trial?

DÉBORA DE MELO GAGLIATO (BRA)

How is the best way to oversee all trials?

DÉBORA DE MELO GAGLIATO (BRA)

1) Is PI involvement necessary in all steps?
2) How to deal with the training of new researchers?
3) Tips: is there a best way to prevent serious deviation?

Giuliano Borges (BRA)

How to retain the patient during the study?

GIULIANO BORGES (BRA)

1) How to deal with the placebo arm?
2) How to deal with the control arm (Same treatment available in routine practice)?
3) Tips: is there any data to show the performance control arm?

Q & A

Coffee Break

MODULE 4 - CLINICAL RESEARCH DIFFICULT SITUATIONS

Table coordinator:
ANDRÉ MATTAR (BRA)
ROBERTO HEGG (BRA)

GRAZIELA ZIBETTI DAL MOLIN (BRA)

What to do if the promised N cannot be achieved?

GRAZIELA ZIBETTI DAL MOLIN (BRA)

1) Changes in the trial design in an ongoing study.
2) Local changes that can directly impact the recruitment.
3) Tips: the best way to signalize the sponsor.

ANDRE SANCHES (BRA)

Controversies over RBM: how not to impact centers with high recruitment rates?

ANDRE SANCHES (BRA)

1) Whats is RBM?
2) Whats mistakes are "acceptable"?
3) Tips: what can be done to not be surprised by serious mistakes.

ANDRESSA AMORIM (BRA)

How to be prepared for an audit/inspection?

ANDRESSA AMORIM (BRA)

1) What are the most common protocol deviations?
2) Is it necessary to review all the patients?
3) Tips: what must be reviewed?

Q & A

Closing

ANDRÉ MATTAR (BRA)
JOSE LUIZ PEDRINI (BRA)
ROBERTO HEGG (BRA)

PSYCHOLOGY
ONLINE + NO TRANSLATION

Coordinators:
ISABELLA BARROS RABELO GONTIJO TUMEH (BRA)
MÁRCIA FARIA VELOSO (BRA)

MODULE 1 - DISTRESS E O MEDO DA RECIDIVA ONCOLÓGICA

Maria da Glória Gimenes (BRA)

Espiritualidade e qualidade de vida: implicações para a prática em oncologia

MARIA DA GLÓRIA GIMENES (BRA)

Sebastião Benício Costa Neto (BRA)

A qualidade de vida como marcador no cuidado do câncer de mama

SEBASTIÃO BENÍCIO COSTA NETO (BRA)

Cristiane Decat Bergerot (BRA)

Distress e o medo da recidiva

CRISTIANE DECAT BERGEROT (BRA)

Fabiana Marthes Molli Caron (BRA)

Diferença de gênero em pacientes e seus parceiros no enfrentamento do câncer

FABIANA MARTHES MOLLI CARON (BRA)

Discussions

LORENA NASCIMENTO MANRIQUE MOLINA (BRA)
MÁRCIA FARIA VELOSO (BRA)

Coffee Break

MODULE 2 - DISCUSSÃO DOS MODELOS DE CONTRATAÇÃO NA PSICO-ONCOLOGIA E O IMPACTO NA ASSISTÊNCIA

Coordinators:
ISABELLA BARROS RABELO GONTIJO TUMEH (BRA)
MÁRCIA FARIA VELOSO (BRA)

MARCO MURILO BUSO (BRA)

Interesses do gestor para o profissional da psico-oncologia

MARCO MURILO BUSO (BRA)

BRUNO FERNANDES BORGINHO (BRA)

Inserção da psico-oncologia no Brasil e resolução que facilitam o trabalho.

BRUNO FERNANDES BORGINHO(BRA)

MATTHEW J. LOSCALZO (BRA)

How to fund psycho-oncology programs

MATTHEW J. LOSCALZO (EUA)

ISABELLA BARROS RABELO GONTIJO TUMEH (BRA)

Disscussions

ISABELLA BARROS RABELO GUNTIJO TUMEH (BRA)

BREAST CANCER PRECEPTORY | MASTERCLASS

FACE-TO-FACE - GUEST ONLY
(DAIICHI SANKYO | ASTRAZENECA + LILLY + MSD)

Coordinators:
ANA CAROLINA SALLES DE MENDONÇA FERREIRA (BRA)
ROSEMAR MACEDO SOUSA RAHAL (BRA)
RUFFO DE FREITAS JUNIOR (BRA)

Opening

Cristiane Nimir (BRA)

MODULE 1 UPDATE ON BREAST PATHOLOGY

Coordinator:
CRISTIANE NIMIR (BRA)

Thiago David Alves Pinto (BRA)

Current challenges in the pathological classification encompassing HER-2 positive and HER-2 low disease

THIAGO DAVID ALVES PINTO (BRA)

Discussion

ANA CAROLINA SALLES DE MENDONÇA FERREIRA  (BRA)
CRISTIANE NIMIR (BRA)

ROSEMAR MACEDO SOUSA RAHAL (BRA)

MODULE 2 HER2-POSITIVE AND HER2 LOW DISEASE

Coordinator:
ROSEMAR MACEDO SOUSA RAHAL (BRA)

DR. MAX SENNA MANO

State of the art treatment of HER-2 positive breast cancer, local/locally advanced disease

MAX MANO (BRA)

Daniel Fontes Santos de Teive Argolo

Treatment sequencing of HER2 positive metastatic breast cancer

DANIEL FONTES SANTOS DE TEIVE ARGOLO(BRA)

Jorge Henrique Santos Leal

Treatment follow-up of HER2 positive metastatic breast cancer

JORGE HENRIQUE SANTOS LEAL (BRA)

Nilceana Maya Aires Freitas

Advances in breast radiotherapy

NILCEANA MAYA AIRES FREITAS (BRA)

Discussion

JOÃO NUNES DE MATOS NETO (BRA)
LEONARDO RIBEIRO SOARES (BRA)

Clinical Cases

10’ Apresentação de caso clínico de câncer de mama metastático
JOÃO NUNES DE MATOS NETO (BRA)

10’ Apresentação de um caso de câncer de mama localizado
LEONARDO RIBEIRO SOARES (BRA)

Coffee Break

DR. MAX SENNA MANO

MODULE 3 TRIPLE NEGATIVE DISEASE

Coordinator:
MAX MANO (BRA)

Elisa Cançado Porto Mascarenhas (BRA)

State of the art treatment of local/locally advanced triple negative breast cancer

ELISA CANÇADO PORTO MASCARENHAS (BRA)

Ana Carolina Salles de Mendonça Ferreira (BRA)

Treatment sequencing of the triple negative metastatic breast cancer treatment

ANA CAROLINA SALLES DE MENDONÇA FERREIRA (BRA)

Andreza Karine de Barros Almeida Souto (BRA)

When should we suggest genetic counseling and what are the prophylactic measures for BRCA mutated patients?

ANDREZA KARINE DE BARROS ALMEIDA SOUTO (BRA)

Discussion

MAX MANO (BRA)
NAYARA PORTILHO ARAUJO (BRA)

Break

Ana Carolina Salles de Mendonça Ferreira (BRA)

MODULE 4 LUMINAL DISEASE

Coordinator:
ANA CAROLINA SALLES DE MENDONÇA FERREIRA (BRA)

Antonio Carlos Buzaid (BRA)

Adjuvant hormone therapy in patients with high-risk luminal disease

ANTONIO CARLOS BUZAID (BRA)

RUFFO DE FREITAS JUNIOR (BRA)

Axillary approach after neoadjuvant therapy

RUFFO DE FREITAS JUNIOR (BRA)

ROMUALDO BARROSO DE SOUSA (BRA)

When can we use genomic signatures to predict the benefit of chemotherapy in patients with HR-positive, HER-2-negative luminal disease?

ROMUALDO BARROSO DE SOUSA (BRA)

Carlos Henrique dos Anjos (BRA)

The state of the art in  HR+, HER2 negative / HER2 low breast cancer

CARLOS HENRIQUE DOS ANJOS (BRA)

Discussion

ALEXANDRE MARCHIORI XAVIER DE JESUS (BRA)
ANA CAROLINA SALLES DE MENDONÇA FERREIRA (BRA)
DANIEL FONTES SANTOS DE TEIVE ARGOLO (BRA)
JORGE HENRIQUE SANTOS LEAL (BRA)

Dinner

WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER

FACE-TO-FACE 

GRUPO ONCOCLÍNICAS

Coordinators:
CRISTIANO AUGUSTO ANDRADE DE RESENDE (BRA)
LEANDRO GONÇALVES OLIVEIRA (BRA)
ROMUALDO BARROSO DE SOUSA (BRA)
VICTOR DOMINGOS LISITA ROSA (BRA)

Leandro Gonçalves Oliveira (BRA)

PART 1 - HORMONE THERAPY

Coordinator:
LEANDRO GONÇALVES OLIVEIRA (BRA)

João Nunes de Matos Neto (BRA)

Adjuvant hormone therapy in high-risk patients: the more, the better?

JOÃO NUNES DE MATOS NETO (BRA)

Discussion

Daniele Assad Suzuki (BRA)

Management of key adverse events in hormone therapy: what is the real evidence?

DANIELE ASSAD SUZUKI (BRA)

Discussion

Cristiano Augusto Andrade de Resende (BRA)

Cyclin inhibitors in different clinical settings: is there room for all of them?

CRISTIANO AUGUSTO ANDRADE DE RESENDE (BRA)

Discussion

Victor Domingos Lisita Rosa (BRA)

Is there life beyond cyclins? Insights in the HR+ Her2 zero setting

VICTOR DOMINGOS LISITA ROSA (BRA)

Discussion

Coffee Break

Cristiano Augusto Andrade de Resende (BRA)

PART 2 - IMMUNOTHERAPY

Coordinator:
CRISTIANO AUGUSTO ANDRADE DE RESENDE (BRA)

DIOCÉSIO ALVES PINTO DE ANDRADE (BRA)

Neoadjuvant Immunochemotherapy - when is it possible to de-escalate the systemic treatment?

DIOCÉSIO ALVES PINTO DE ANDRADE (BRA)

Discussion

ROMUALDO BARROSO DE SOUSA (BRA)

Thinking outside the box in the advanced disease: new biomarkers and immunotherapy indications

ROMUALDO BARROSO DE SOUSA (BRA)

Discussion

Whemberton Martins de Araújo (BRA)

FDG PET-CT for assessment of response to immunotherapy: Patterns and Pitfalls

WHEMBERTON MARTINS DE ARAÚJO (BRA)

Discussion

Ana Cláudia Gonçalves Lima (BRA)

When to consider and manage immune-mediated adverse events

ANA CLÁUDIA GONÇALVES LIMA (BRA)

Discussion

Victor Domingos Lisita Rosa (BRA)

PART 3 - PRECISION MEDICINE

Coordinator:
VICTOR DOMINGOS LISITA ROSA (BRA)

Andreza Karine de Barros Almeida Souto (BRA)

Clinical implications of germline testing in breast cancer

ANDREZA KARINE DE BARROS ALMEIDA SOUTO (BRA)

FRANKLIN FERNANDES PIMENTEL (BRA)

Analysis of potential molecular markers for breast cancer

FRANKLIN FERNANDES PIMENTEL (BRA)

Carlos Henrique dos Anjos (BRA)

Circulating tumor cells and liquid biopsies, translation to clinical practice

CARLOS HENRIQUE DOS ANJOS (BRA)

Leandro Gonçalves Oliveira (BRA)

Precision medicine in metastatic breast cancer: clinical case

LEANDRO GONÇALVES OLIVEIRA (BRA)

Discussion

Coffee Break

ROMUALDO BARROSO DE SOUSA (BRA)

PART 4 - ADCs

Coordinator:
ROMUALDO BARROSO DE SOUSA (BRA)

Daniele Assad Suzuki (BRA)

What will be the status of the treatment algorithm within metastatic HER2-positive disease with the introduction of trastuzumab-deruxtecan?

DANIELE ASSAD SUZUKI (BRA)

Helenice Gobbi (BRA)

HER2-low disease: the pathologist view

HELENICE GOBBI (BRA)

Carlos Henrique dos Anjos (BRA)

Treatment algorithm of the advanced HR+ diseases within ADC era

CARLOS HENRIQUE DOS ANJOS (BRA)

Cristiano Augusto Andrade de Resende (BRA)

Treatment algorithm of the advanced triple negative disease within ADC era

CRISTIANO AUGUSTO ANDRADE DE RESENDE (BRA)

ROMUALDO BARROSO DE SOUSA (BRA)

What’s next in terms of breast cancer treatment with ADCs

ROMUALDO BARROSO DE SOUSA (BRA)

Discussion

4ª REUNIÃO DE INVESTIGADORES DO ESTUDO VENUS
(RESTRITO À CONVIDADOS)
FACE-TO-FACE

Coordinador:
GIULIANO MENDES DUARTE (BRA)
Secretária:
MARIA BEATRIZ KRAFT (BRA)

Abertura e apresentações

Danielle Cristina Miyamoto Araújo (BRA)

Fluxograma do estudo, atualização da estatística e estimativa de recrutamento

DANIELLE CRISTINA MIYAMOTO ARAÚJO (BRA)

Giuliano Mendes Duarte (BRA)

Como fica o estudo VENUS após os resultados do estudo SOUND

GIULIANO MENDES DUARTE (BRA)

RUFFO DE FREITAS JUNIOR (BRA)

Como superar as barreiras para realização de ensaios clínicos no Brasil

RUFFO DE FREITAS JUNIOR (BRA)

Debate

1. Unicampo - GIULIANO MENDES DUARTE
2. Unisp - EDUARDO CARVALHO PESSOA
3. Barretos - IDAM OLIVEIRA
4. PUC campinas - JÚLIO NARCISO GOMES
5. UFMG - CLÉCIO ENIO MURTA DE LUCENA
6. Hospital do cancer de Muriaé - RENÉ ALOISIO DA COSTA VIEIRA
7. Hospital Federal da lagoa - RAFAEL MACHADO
8. UFPR - VINÍCIUS MILANI BUDEL
9. UFRS - ANDREA DAMIN
10. Hospital Geral de Fortaleza - FRANCISCO PIMENTEL
11. Liga contra o cancer RN - ROBERTA JALES
12. Hospital Barao de Lucena - DARLEY DE LIMA FERREIRA FILHO
13. UFG - ROSEMAR MACEDO SOUSA RAHEL
14. Maternidade Dona Iris - LEONARDO RIBEIRO